Imagine sitting down to enjoy a meal, only to feel nauseated, painfully full or bloated for hours afterward. For many people living with gastroparesis, symptoms like these can become part of daily life.
Gastroparesis is a gastric neuromuscular disorder in which the stomach empties food more slowly than normal without a mechanical blockage. Current treatments can help manage symptoms, but they do not address the underlying biological mechanisms that may drive the disease.
“To develop better treatments, we first need to understand how the healthy stomach works and, just as importantly, what happens to those cells when disease strikes,” said Rajan Singh, Ph.D., assistant professor of research in the Department of Physiology and Cell Biology.
That question is now at the center of a new National Institutes of Health-funded research program at the 91·çÃùÄñ³ª School of Medicine (UNR Med).
Singh received his first NIH R01 award from the National Institute of Diabetes and Digestive and Kidney Diseases. As the sole principal investigator, he will lead the project “Gut-resident macrophage regulation of gastric dysmotility and barrier dysfunction in gastroparesis.”
From Springboard support to NIH funding
The award builds on support Singh received through UNR Med's , a program funded by the Redfield Foundation that helps early-career investigators generate the evidence needed to compete for external research funding
In 2024, Singh received Springboard funding to investigate how microRNA may regulate gut-resident macrophages in gastroparesis. The support allowed him to strengthen preliminary findings, refine the project's scientific focus and gather the data needed for a larger federal grant application.
“The Springboard Research Award came at a critical stage in the development of this project,” Singh said. “It gave us the opportunity to strengthen the preliminary evidence, refine the biological hypothesis and build the foundation needed to compete for federal funding.”
Over the following year, Singh expanded the research and generated additional data supporting the central hypothesis. He submitted an R01 application to NIDDK in October 2025 and received in September 2026.
“There is often a gap between having an innovative idea and having enough evidence to compete successfully for major federal funding," Singh said. "Strategic seed funding helps bridge that gap.”
The research centers on macrophages — immune cells that do much more than defend against infection. In the gut, some macrophages help maintain the protective intestinal lining, while others reside near nerves and specialized pacemaker cells that coordinate stomach movement.
Previous human and experimental studies have linked changes in macrophage populations with delayed gastric emptying and damage to gastrointestinal pacemaker cells. However, researchers still do not know whether those changes simply occur alongside the disease or actively contribute to it.
“We are beginning to understand that macrophages are not simply immune cells arriving after damage has already occurred,” Singh said. “They are part of a much larger cellular communication network involving nerves, pacemaker cells, the epithelial barrier and other cells that keep the gastrointestinal tract functioning normally.”
Using genetic models, physiological measurements, single-cell analyses and human tissue samples, Singh and his collaborators will investigate three key questions: how macrophages influence gastric motility, how they affect the gastrointestinal barrier and whether abnormal macrophage states can be reprogrammed to improve disease processes.
Human biopsy samples obtained through clinical collaborations will help connect findings from experimental models with what researchers observe in patients living with gastroparesis.
“Our goal is to understand how these macrophages change in disease, what those changes do to the stomach and ultimately whether we can intervene,” Singh said. “If we understand the mechanism, we can begin asking whether those changes can be prevented or reversed.”
Building on earlier discoveries
The project builds on Singh's previous research published in examining microRNA regulation in gastrointestinal disorders. That work raised broader questions about whether microRNA-mediated changes in gut-resident macrophages could contribute to gastroparesis and other forms of gastrointestinal dysfunction.
The NIH-funded study expands that work by exploring how immune cells interact with the broader cellular networks that regulate motility, inflammation and barrier function.
“Gastroparesis will not be solved by looking at one cell type or one measurement in isolation,” Singh said. “The opportunity now is to understand how these cellular systems interact at the neuroimmune axis and use that knowledge to move toward treatments directed at the biology present in individual patients.”
Looking ahead
For Singh, receiving his first R01 marks an important milestone and provides an opportunity to pursue new scientific questions while training the next generation of researchers.
“Receiving my first R01 is deeply meaningful to me, but I also see it as a responsibility,” Singh said. “It gives us the opportunity to pursue challenging scientific questions, mentor the next generation of scientists, and build an independent research program focused on underlying gastrointestinal disorders that could ultimately matter to patients.”
If successful, the project could identify biomarkers of macrophage dysfunction and reveal biological pathways that may eventually become targets for new therapies.
“Science rarely advances in a single leap,” Singh said. “This award reflects years of experiments, setbacks, collaboration, mentorship and persistence, and an early institutional investment that gave the idea room to grow.”